StreetInsider.com News Articles

Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Post Release of Setmelanotide Data

Mon, 15 Jun 2026 09:31:52 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $133.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).

The analyst commented, "We're reiterating our Buy rating on RYTM following the release of 6-month setmelanotide data in PWS, which overall look encouraging, with an improved effect on weight loss vs the prior cut, and an effect on hyperphagia that looks clearly superior to prior placebo effects. The biggest caveat continues to be that this is a small single-arm study, though this nitpick is counterbalanced by commentary from the primary investigator (Dr. Jen Miller) that these are some of her most severe patients that

Rhythm Pharmaceuticals (RYTM) PT Raised to $155 at Wells Fargo

Mon, 15 Jun 2026 07:21:20 -0400

Wells Fargo analyst Derek Archila raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $155.00 (from $144.00) while maintaining a Overweight rating.

Rhythm Pharmaceuticals reports positive Phase 2 data for PWS treatment

Sat, 13 Jun 2026 08:01:14 -0400

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) announced interim six-month results from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). The trial enrolled 18 patients aged 6-23 years, with 17 remaining on active therapy as of June 12, 2026.

The data, presented at the Endocrine Society's Annual Meeting, showed a 3.06% mean reduction in BMI across 17 patients at month six. Adult patients experienced a 3.11% mean BMI reduction, with six achieving greater than 2.5% reduction and four achieving greater than 4% reduction. Pediatric patients showed a 3.00% mean BMI reduction and a 0.35 mean reduction in BMI z-score

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Sat, 13 Jun 2026 08:01:00 -0400

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

-- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET --

BOSTON, June 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Sat, 13 Jun 2026 08:01:00 -0400

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

-- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET --

BOSTON, June 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of

Rhythm Pharmaceuticals schedules call on Prader-Willi syndrome trial data

Fri, 12 Jun 2026 16:01:15 -0400

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) announced it will host a conference call on June 13 at 9:00 a.m. ET to discuss interim six-month results from its Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome.

David Meeker, the company's chairman, president and chief executive officer, will present the data alongside Jennifer Miller, a pediatric endocrinologist from the University of Florida College of Medicine.

The company will provide both a live conference call and webcast for the presentation. A recorded version will be available on the company's website approximately two hours after the call and remain accessible for 30 days.

Setmelanotide, marketed as

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Fri, 12 Jun 2026 16:01:00 -0400

BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company’s Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).

David Meeker, M.D., Chairman, President and Chief Executive Officer will be joined by Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine to discuss the

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Fri, 12 Jun 2026 16:01:00 -0400

David Meeker, M.D., Chairman, President and Chief Executive Officer will be joined by Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine to discuss the

Rhythm Pharmaceuticals (RYTM) Reiterated at Market Outperform by Citizens

Wed, 03 Jun 2026 04:43:01 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $155.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).

The analyst commented, " We continue to like setmelanotide’s expansion into Prader-Willi Syndrome (PWS), supported by early evidence that MC4R agonism can deliver a differentiated clinical profile— most notably with meaningful BMI reductions, which has not been demonstrated with the only FDA-approved therapy, Vykat XR. While comparisons are limited by small sample size, open-label design, and cross-trial differences, the early hyperphagia signal appears at least comparable to Vykat XR, with the added benefit of weight loss. RYTM shares climbed to >$115 when the

Form DEFA14A RHYTHM PHARMACEUTICALS,

Fri, 29 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260529/26575190.html

Form DEFA14A RHYTHM PHARMACEUTICALS,

Fri, 29 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260529/26575190.html

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

Fri, 29 May 2026 08:00:00 -0400

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.

Jennifer Miller, M.D., Pediatric Endocrinology, University of Florida College of Medicine, will present results from an ongoing Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), evaluating higher doses and longer treatment duration. The

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

Fri, 29 May 2026 08:00:00 -0400

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

Thu, 28 May 2026 08:00:00 -0400

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed American Journal of Medical Genetics.